---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022908"
form_type: "8-K"
ticker: null
cik: "0001362703"
company_name: "THERALINK TECHNOLOGIES, INC."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:45:25.113354+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theralink appoints Faith Zaslavsky as CEO; Mick Ruxin becomes CMO

## Summary
- Faith Zaslavsky appointed CEO effective June 26, 2023; previously President and COO since December 2022.
- Former CEO Mick Ruxin transitions to Chief Medical Officer.
- Company is in process of merging with IMAC Holdings, Inc. (NASDAQ: BACK).
- Zaslavsky has over 23 years of genomics experience, including commercializing BRCA tests.

## SEC filing metadata
- accession: 0001493152-23-022908
- form_type: 8-K
- cik: 0001362703
- company_name: THERALINK TECHNOLOGIES, INC.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/0001493152-23-022908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022908
- JSON: https://secwatch.observer/filing/0001493152-23-022908.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022908.txt

## Key facts
- Executive change
  Faith Zaslavsky was appointed as Chief Executive Officer at THERALINK TECHNOLOGIES, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/0001493152-23-022908-index.htm
- Executive change
  Mick Ruxin changed role as Chief Medical Officer at THERALINK TECHNOLOGIES, INC..
  - Action: transitioned
  - Role: Chief Medical Officer
  source text: The Company’s former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/0001493152-23-022908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.